Alzheimer's Disease
Also known as: AD, Alzheimer Dementia, Senile Dementia of the Alzheimer Type
2x
the rate of Alzheimer's and other dementias in older Black Americans compared to older white Americans (Alzheimer's Association, 2024 Facts and Figures)
Overview
Alzheimer's disease is a progressive brain disorder that destroys memory, language, judgment, and the ability to carry out daily life. It is the most common cause of dementia, accounting for an estimated 60 to 80 percent of cases. The hallmarks are amyloid-beta plaques and tau tangles that accumulate in the brain years, often decades, before symptoms show up. The Alzheimer's Association's 2024 Facts and Figures report estimates 6.9 million Americans age 65 and older are living with Alzheimer's dementia, with that number projected to nearly double by 2060.
Alzheimer's is not normal aging. Forgetting a name and recalling it later is aging. Forgetting the name of your daughter, the route home from a store you have shopped at for thirty years, or how to use the stove is not. The disease typically begins with subtle memory and word-finding problems, then advances over years into impaired judgment, disorientation, personality change, and eventual loss of independence. There is no cure. Diagnosis is clinical, supported by cognitive testing, brain imaging, and increasingly by blood and cerebrospinal-fluid biomarkers that detect amyloid and tau.
How Alzheimer's Disease affects Black patients
Older Black Americans carry roughly twice the burden of Alzheimer's and related dementias as older white Americans. The Alzheimer's Association's 2024 Facts and Figures report puts the prevalence at 21.3 percent among Black Americans age 70 and older. The 2024 report also documents that only 20 percent of Black Americans say they face no barriers to excellent dementia care, only 48 percent feel confident they can access culturally competent care, and half report experiencing discrimination while seeking care for a loved one with dementia.
Diagnosis comes late. Gianattasio and colleagues, publishing in Alzheimer's and Dementia: TRCI in 2019 (PubMed 31890853), found non-Hispanic Black patients had roughly twice the risk of underdiagnosed or missed dementia compared with non-Hispanic whites. Black beneficiaries are more likely than white beneficiaries to receive their first dementia diagnosis in an emergency room or skilled-nursing facility rather than primary care, meaning the disease has already advanced before the system catches up.
Treatment access lags too. A 2022 analysis in Alzheimer's and Dementia (PMC9402814) found Black and Hispanic patients were significantly less likely than white patients to initiate cholinesterase inhibitors or memantine after a dementia diagnosis, and less likely to stay on them. Referral to a neurologist narrows the gap, which points the finger at primary-care prescribing patterns and specialist access, not patient preference.
Vascular risk drives a chunk of the prevalence difference. Hypertension, type 2 diabetes, and stroke are more common and start earlier in Black adults, and each of those independently damages the small vessels of the brain. Most older Black adults who develop dementia have mixed pathology: Alzheimer plaques plus vascular injury.
The APOE-4 story is genuinely different in people of African ancestry. The Reiman/Logue group's 2022 PLOS Genetics paper identified a locus near APOE on chromosome 19q13.31 that substantially reduces APOE-4-driven Alzheimer's risk on African-ancestry haplotypes; the odds ratio for APOE-4 homozygotes drops from about 7 to about 2 when the protective variant is present. The textbook line that APOE-4 means the same thing in every population is wrong, and clinicians ordering genetic testing should know that.
Lecanemab (Leqembi) and donanemab (Kisunla), the new anti-amyloid antibodies approved for early Alzheimer's, have a representation problem. In the lecanemab CLARITY-AD trial, Black participants made up roughly 2 to 3 percent of enrollment, per published baseline data; donanemab's TRAILBLAZER-ALZ 2 trial enrolled approximately 4 percent Black participants in the US arm. The drugs require confirmed brain amyloid for eligibility, and screening data show Black candidates are far more likely to be screened out for not meeting the amyloid threshold, which raises an unresolved question about whether amyloid-targeting therapy works as well, or is even the right target, in Black patients whose dementia is more often mixed pathology.
The caregiver economy rests on Black women. The Family Caregiver Alliance and the Alzheimer's Association report that African-American dementia caregivers provide an average of about 20 hours of unpaid care per week, are more likely than white caregivers to live with the person they care for, and more than half are simultaneously caring for a child under 18 or another older relative.
Symptoms
The Alzheimer's Association teaches ten warning signs. Any one of them, especially if it is a change from how you or your relative used to be, is worth a doctor visit.
- Memory loss that disrupts daily life: asking the same question over and over, forgetting recent conversations, leaning hard on sticky notes and family reminders for things you used to handle yourself.
- Trouble planning or solving problems: losing track of monthly bills, following a recipe you have cooked for years, or keeping numbers straight.
- Difficulty completing familiar tasks: getting lost driving to church, the grocery store, or work.
- Confusion with time or place: losing track of dates, seasons, or how you got somewhere.
- Trouble with visual images and spatial relationships: difficulty reading, judging distance, or recognizing your own face in the mirror.
- New problems with words when speaking or writing: stopping in the middle of a sentence, calling things by the wrong name.
- Misplacing things and losing the ability to retrace steps: putting the remote in the refrigerator, then accusing family of stealing.
- Decreased or poor judgment: giving away large sums to a phone scammer, neglecting hygiene, dressing for the wrong weather.
- Withdrawal from work, church, or social activity.
- Changes in mood and personality: new suspicion, anxiety, depression, irritability, or fearfulness, especially outside the home.
When to see a doctor
Get evaluated when memory or thinking changes start interfering with daily function. Concrete triggers: getting lost in a neighborhood you know, missing medications repeatedly, mismanaging bills you have always handled, a noticeable shift in personality or judgment, or family members independently noticing the same things you do.
The 55 percent of Black Americans who, per the Alzheimer's Association's 2024 survey, believe significant memory loss is a normal part of aging are wrong, and that belief delays diagnosis. It is not normal. A workup early in the course is when you have the most treatment options, including the new anti-amyloid drugs, which only work in early disease. Sudden confusion, a fall with new disorientation, or rapid decline over weeks rather than years is not Alzheimer's pattern and warrants urgent evaluation for stroke, infection, medication effect, or delirium.
Screening
There is no universal population screening for Alzheimer's in asymptomatic adults. Medicare's Annual Wellness Visit, available yearly at no cost to beneficiaries, is required to include a cognitive impairment check. If anything is flagged, the visit can convert to a billable Cognitive Assessment and Care Plan Service, which CMS pays for separately.
The brief tools used at this stage are the Mini-Cog (a three-item recall plus a clock-drawing test, takes three minutes), the Montreal Cognitive Assessment (MoCA, 30 points, more sensitive to mild impairment), and less often the MMSE or SLUMS. None of these diagnoses Alzheimer's by itself. An abnormal screen should lead to a full evaluation: structured history with a family member present, neurological exam, blood work to rule out thyroid disease and B12 deficiency, MRI to look for stroke, atrophy, or vascular damage, and increasingly amyloid PET or a blood biomarker if a disease-modifying drug is being considered.
Collateral history from family is decisive. The person with early Alzheimer's often does not perceive their own deficits, or covers smoothly in a short office visit. A daughter, son, or spouse who can describe what has changed over the past one to two years gives the clinician information no cognitive test can replace.
Treatment overview
Treatment is symptomatic, disease-modifying in narrow cases, and heavily non-pharmacologic.
Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) modestly improve or stabilize cognition and daily function in mild-to-moderate disease. Memantine, an NMDA-receptor antagonist, is added in moderate-to-severe disease. None of these stop progression. They buy function and time, often six to twelve months of measurable benefit. Black patients are prescribed these drugs at significantly lower rates than white patients with the same diagnosis, a gap that narrows when a neurologist is involved.
Lecanemab (Leqembi) and donanemab (Kisunla) are anti-amyloid monoclonal antibodies approved for mild cognitive impairment or mild dementia due to Alzheimer's with biomarker-confirmed amyloid. They slow decline by roughly 25 to 35 percent over 18 months in the pivotal trials. They are infused IV, require frequent MRI monitoring for ARIA (amyloid-related imaging abnormalities, which can include brain swelling and microhemorrhages), and the published trials enrolled very few Black participants, so subgroup efficacy and safety in Black patients are genuinely unknown. APOE-4 homozygotes have higher ARIA risk in the trial data.
Non-pharmacologic care does most of the work. Structured daily routine, environmental cues, treatment of hearing loss (a major modifiable risk factor), physical activity, social engagement, and aggressive control of blood pressure, diabetes, and cholesterol are all evidence-based. Behavioral symptoms (agitation, sleep disturbance, suspicion) should be approached first with non-drug strategies: identify triggers, simplify environment, address pain and constipation, adjust caregiver communication. Antipsychotics in dementia carry a black-box warning for increased mortality and should not be the first move.
Caregiver support is part of the treatment plan. Caregiver burnout predicts nursing-home placement of the patient more strongly than the patient's own disease severity.
Questions to ask your doctor
Bring this list to your next appointment.
- I (or my family) have noticed memory changes. Can we do a formal cognitive assessment today, like the Mini-Cog or MoCA?
- Can I get an MRI to look for stroke or vascular contribution to my symptoms, not just an Alzheimer's workup?
- If this is Alzheimer's, am I a candidate for lecanemab or donanemab? What does the eligibility workup look like and what is your honest read on the trial data in Black patients?
- Are there clinical trials enrolling at the local Alzheimer's Disease Research Center that I should consider?
- Can you refer me to a neurologist or memory clinic, even if I do not have a confirmed diagnosis yet?
- What caregiver support resources do you connect families to? Is there a social worker or care navigator on this team?
- I want to talk about advance care planning now, while I can. Can we set up a visit for that and document a healthcare proxy?
- What is my blood pressure target and my A1C target, given the link between vascular risk and dementia progression?
Find a Neurology
Search our directory of verified Black health providers who specialize in neurology.
Browse Neurology providersMedical disclaimer
This content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. If you are experiencing a medical emergency, call 911 or your local emergency number immediately.